Therapeutic Drug Monitoring for Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease

Dr. Abhinav Vasudevan from Eastern Health Box Hill Hospital in Melbourne reviewed therapeutic drug monitoring (TDM) for non-TNF biologics and small molecule treatments in IBD. Findings showed better responses with higher levels of vedolizumab, ustekinumab, and risankizumab, but insufficient data supports routine TDM for dose adjustments outside anti-TNF therapies.